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1  | INTRODUC TION
CLKT is a preferred option for patients with chronic organ failure 
altering both the liver and the kidney according to a hepatocentric 
approach.1 More than 8000 CLKTs have been performed, more than 
300 of them to pediatric patients in the United States to date.2 In 
Scandinavia, 0.5% (10/1915) of transplanted patients received com‐
bined liver and kidney transplants in 2016.3 Large registry studies 
have reported five‐year patient survival of 76% and 82% after adult 
and pediatric CLKT, respectively.4,5
Five‐year cumulative incidence of CKD, depending on definition and 
population, varies from 3% to 18% after LT.6‐8 The prevalence of CKD 
was 25% up to six months after CLKT in small study.9 We have previ‐
ously shown that GFR remains relatively stable from one up to five years 
after adult and pediatric LT and also after pediatric KT.10‐12 Others have 
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Abstract
It has been proposed that the liver protects the kidney in CLKT. However, few studies 
have examined long‐term renal function after CLKT and contrasted renal function of 
CLKT patients to KT patients beyond one year after transplantation. We studied 
long‐term renal function of CLKT patients and compared renal function of CLKT pa‐
tients to KT patients between one and five years after transplantation. Patients who 
underwent CLKT between 1993 and 2011 were included (n = 34; 11 children and 23 
adults). Ninety‐six (27 children and 69 adults) KT patients were selected as controls. 
GFR was estimated (eGFR) and measured (mGFR) with 51Cr‐EDTA	clearance.	Mean	
mGFR was 63 at one and 70 at ten years after pediatric CLKT. Mean eGFR was 75 at 
one and 50 at ten years after adult CLKT. Difference in mean mGFR between pediat‐
ric	CLKT	and	KT	patients	was	8	(95%	CI	−7	to	23)	and	11	(95%	CI	−4	to	26)	at	one	and	
five years after transplantation, respectively. Difference in mean eGFR between 
adult	CLKT	and	KT	patients	was	8	(95%	CI	−5	to	20)	and	1	(95%	CI	−10	to	12)	at	one	
and five years after transplantation, respectively. Longitudinal changes in GFRs were 
somewhat similar in CLKT and KT patients in both age‐groups but pediatric CLKT 
patients had on average higher GFRs than pediatric KT patients. In long‐term follow‐
up, renal function remains stable in pediatric CLKT patients but declines in adult 
CLKT patients.
K E Y W O R D S
adult, combined liver‐kidney transplantation, glomerular filtration rate, kidney transplantation, 
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2 of 10  |     KIVELÄ Et aL.
reported that GFR remains steady or slightly worsens up to five years 
after adult and pediatric CLKT.13‐16 Only few studies have contrasted 
renal function of CLKT patients to renal function of KT patients, espe‐
cially with a follow‐up period beyond one year after transplantation.15,16
Our aim was to study long‐term renal function in pediatric and 
adult CLKT patients in a single center. We also compared renal func‐
tion of CLKT patients to renal function of KT patients in both age‐
groups separately between one and five years after transplantation.
2  | MATERIAL S AND METHODS
2.1 | Patients
All	adult	and	pediatric	(age	≤	16	years)	patients	who	underwent	de‐
ceased donor CLKT between 1993 and 2011 at Helsinki University 
Hospital (HUH) were included in our longitudinal study (n = 34; 23 
adults and 11 children). One pediatric patient deceased less than one 
month after CLKT; 10 pediatric patients were thus included in the 
final analyses. The clinical follow‐up of these patients is organized 
by the Departments of Transplantation and Liver Surgery (adult unit) 
and Pediatric Nephrology and Transplantation (pediatric unit). Both 
of these departments are a part of HUH where all transplantations 
in Finland are performed, more than 8000 KT and more than 1000 
LT to date. The first CLKT for an adult and pediatric patient was per‐
formed in 1993 and 1999, respectively.
Three KT patients were selected as controls for every CLKT pa‐
tient. Control patients were matched with regard to gender, age at 
transplantation (±two years) and transplantation year (± two years). 
Instances in which more than three control patients were match‐
able (ie, same gender, age at transplantation within ± two years 
and transplantation year within ± two years), selection of three 
controls was primarily based on age so that age instead of trans‐
plantation year was kept as close as possible between the CLKT 
and KT patients. In addition, pediatric patients were matched (if 
feasible) within pubertal stage (ie, a prepubertal CLKT patient was 
not matched with a pubertal KT patient). Control patients with a 
re‐transplant, transplant from a living donor, follow‐up less than 
one year after transplantation, and with congenital nephrosis of the 
Finnish	 type	with	 recurrent	 nephrosis	were	 excluded.	 All	 control	
patients were manually selected from the list of consecutive KT in 
Finland.
Patients'	medical	 records	 and	 national	 transplantation	 registry	
were used to retrieve clinical information. This study is part of re‐
search projects which have been approved by the ethics committees 
of the Hospital District of Helsinki and Uusimaa (application number 
345/13/03/03/2008 and 268/13/03/02/2010).
2.2 | Immunosuppression
Triple	immunosuppression	with	CsA,	AZA,	and	MP	was	used	as	ini‐
tial	immunosuppression.	CsA	was	switched	to	TAC	and	AZA	to	MMF	
on an individual basis if clinically indicated. In pediatric patients, 
basiliximab was used as induction since 1999.
In	adults,	MMF	was	used	since	2006	and	TAC	was	given	to	immu‐
nologically unstable patients and if patient was in a trial. In addition, 
MP withdrawal was target within 12 months except in autoimmune 
liver diseases in adult patients.
For	pediatric	patients,	CsA	and	TAC	target	trough	levels	were	60	
to 100 μg/L and 4 to 6 μg/L, respectively, at one year after trans‐
plantation	 and	 thereafter.	 For	 adult	 patients,	 CsA	 and	 TAC	 target	
trough levels were 70 to 150 μg/L and 5 to 10 μg/L, respectively, at 
one year after transplantation and thereafter.
Immunosuppression	at	one	year	after	transplantation,	and	CsA	
and	TAC	trough	levels	at	one,	three	and	five	years	after	transplanta‐
tion are shown in Tables S1 and S2.
2.3 | Acute kidney rejections
Acute	 kidney	 rejections	 were	 recorded	 up	 to	 three	 months	 after	
transplantation since most of these rejections occur within this time‐
frame. Data on these rejections are also more thorough in medical 
records or in our national transplantation registry. Diagnosis of re‐
jection was based on fine‐needle aspiration or core‐needle biopsy.
2.4 | Renal function
GFR was measured (mGFR) with plasma51Cr‐EDTA	clearance	as	part	
of routine clinical follow‐up for both pediatric CLKT and KT patients, 
and cross‐sectionally as part of the study in a subsample of adult 
CLKT	 patients.	 Measured	 GFRs	 taken	 before	 the	 end	 of	 January	
2006 were corrected for one‐pool approximation with an averaged 
Bröchner‐Mortensen Equation. 17 GFR was estimated (eGFR) with 
the bedside Schwartz equation [0.413 × (height (cm)/creatinine (mg/
dL))] 18 in pediatric patients and with the CKD‐EPI Equation 19 in 
adult patients.
Throughout, GFRs are shown as rounded to the nearest whole num‐
ber unless otherwise specified and with the unit of mL/min/1.73 m2.
2.5 | Statistics
Statistical analyses were performed with Stata 12.1 (StataCorp LP, 
College	Station,	TX,	USA)	and	R	3.1.1	 (R	Foundation	for	Statistical	
Computing,	Vienna,	Austria).	Continuous	variables	are	presented	as	
means and SD and as medians and IQR if indicated. IQRs were cal‐
culated with the method recommended by Hyndman et al20 Survival 
curves were constructed with the Kaplan‐Meier method.
Comparison of mean GFRs between CLKT and KT groups was con‐
ducted separately for time‐points at one, three, and five years after 
transplantation	with	Welch's	t test (primary GFR analysis). In addition, 
comparison of mean change of GFRs (ie, obtaining GFR change for every 
patient and taking mean change across all patients) from one to three 
(GFR at three minus one) and three to five (GFR at five minus three) years 
after transplantation between CLKT and KT groups was conducted with 
Welch's	 t test (secondary GFR analysis). In sensitivity analysis, due to 
potential skewness of GFRs, medians were compared according to the 
Bonett‐Price method 21 with a user‐written Stata module.22
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In additional GFR analysis for adult patients, linear mixed mod‐
els were specified with eGFR as a response variable and group as a 
main predictor variable.Matched factors (ie, age at transplantation, 
gender, and transplantation year) were also adjusted. Random inter‐
cept models were specified in such a way that patients (n = 92 with 
263 eGFRs) were nested within clusters (n = 23; ie, one CLKT pa‐
tient and three KT control patients within one cluster). Mixed model 
analyses were carried out with R packages lme4 and lmerTest.23,24 
Additional	details	are	provided	in	Table	S3.	Residuals	were	inspected	
with quantile‐quantile plots, and no severe deviation from normality 
was observed.
A	pairwise	comparison	of	mean	GFRs	at	one	to	ten	years	after	
CLKT was conducted with paired t test. In sensitivity analysis to 
check robustness of CI for difference in pairwise means, bootstrap 
with 5000 resamples was used to obtain bias‐corrected and accel‐
erated CIs.
Comparison	of	two	GFR	methods	(ie,	eGFR	and	mGFR)	with	LOA	
was made with a user‐written Stata module.25 Correlation coeffi‐
cients	between	eGFRs	and	CsA/TAC	trough	levels	were	calculated	
with a user‐written Stata module.26
3  | RESULTS
3.1 | Patients
The characteristics of the 34 CLKT patients are shown in Table 1. 
Of the 11 pediatric CLK recipients, six (54.5%) were transplanted 
with reduced‐sized liver grafts. One pediatric CLKT patient de‐
ceased less than one month after transplantation, which is why 
KT control patients were only selected for 10 CLKT pediatric pa‐
tients.	A	total	of	27	pediatric	KT	control	patients	were	selected	
due to overlapping patients (two or three control patients for 
every pediatric CLKT patient). The characteristics of the 96 con‐
trol KT patients are shown in Table 2. Mean donor age of the 
10 pediatric CLKT patients was lower compared to pediatric KT 
patients (16.2 years versus 37.8 years). Difference in donor age 
was	more	evident	with	medians	(11.3	versus	39.0).	Age	at	the	time	
of transplantation was similar in both adult (44.4 and 44.8 years) 
and pediatric (5.3 and 4.9 years) patients between CLKT and KT 
groups.
Of the 10 pediatric CLKT patients, three (30.0%) had biopsy‐con‐
firmed acute cellular kidney rejections compared to nine (33.3%) pe‐
diatric KT patients up to three months after transplantation. On the 
contrary, none of the adult CLKT patients experienced acute cellular 
kidney rejections compared to 10 out of 69 (14.5%) adult KT patients 
up to three months after transplantation.
3.2 | Survival of CLKT patients
Five‐year patient survival was 91% (95% CI 51% to 99%) for pediatric 
and 96% (95% CI 73% to 99%) for adult CLKT patients (Figure 1). 
Nine patients (26.5%; two pediatric and seven adult) deceased dur‐
ing the follow‐up.
3.3 | Renal function
3.3.1 | Estimated GFR in pediatric patients
In pediatric patients, eGFRs were on average higher in CLKT 
than in KT patients (for instance, mean eGFR 82 vs 63 at 1 year) 
(Figure	2A,B).	Both	pediatric	patient	groups	exhibited	more	or	less	
similar change in eGFR during the follow‐up. Differences in mean 
and median eGFR (primary GFR analysis) between groups are shown 
in Table 3.
TA B L E  1   Characteristics of 34 CLKT patients
 
Adult patients 
(N = 23)
Pediatric 
patients (N = 11)
Gender, n (%)
Male 11 (47.8) 4 (36.4)
Female 12 (52.2) 7 (63.3)
Mean (SD) age at CLKT, 
years
44.4 (16.7) a  4.9 (4.3) b 
Mean (SD) CIT, hours
Liver 6.6 (2.5) c  5.4 (1.7) d 
Kidney 11.3 (2.9) e  8.1 (1.8) f 
Mean (SD) donor age, 
years
37.2 (15.2) g  16.6 (14.4) h 
CLK as first transplant, n (%)
Yes 16 (69.6) 8 (72.7)
No 7 (30.4) 3 (27.3)
Primary indication for CLKT, n (%)
PKD 6 (26.1) 7 (63.6)
Metabolic disorder ‐ 3 (27.3)
Alcoholic	cirrhosis 3 (13.0) ‐
Chronic liver rejection 3 (13.0) ‐
Cryptogenic cirrhosis 2 (8.7) ‐
Other 9 (39.1) 1 (9.1)
CLKT era, n (%)
1992‐1996 1 (4.3) ‐
1997‐2001 5 (21.7) 2 (18.2)
2002‐2006 12 (52.2) 4 (36.4)
2007‐2011 5 (21.7) 5 (45.5)
One pediatric CLKT patient deceased less than one month after trans‐
plantation. Values for 10 pediatric patients are shown in footnotes.
aMedian (IQR) 44.6 (25.0 to 58.9) 
bMedian (IQR) 2.5 (1.5 to 8.4). Mean (SD) 5.3 (4.3) and median (IQR) 3.3 
(1.7 to 8.7) for 10 patients. 
cMedian (IQR) 6.2 (5.1 to 8.4) 
dMedian (IQR) 5.2 (4.4 to 6.9). Mean (SD) 5.2 (1.7) and median (IQR) 5.1 
(4.2 to 5.7) for 10 patients. 
eMedian (IQR) 11.1 (9.0 to 12.9), n = 22 
fMedian (IQR) 8.0 (6.5 to 9.7). Mean (SD) 8.0 (1.9) and median (IQR) 8.0 
(6.3 to 9.8) for 10 patients. 
gMedian (IQR) 38.9 (19.3 to 49.4) 
hMedian (IQR) 15.0 (6.1 to 20.1). Mean (SD) 16.2 (15.2) and median (IQR) 
11.3 (5.6 to 21.8) for 10 patients. 
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In secondary GFR analysis, mean (SD) change in eGFR from 
one to three years was 20 (24) after CLKT and 8 (17) after KT 
[difference	 in	mean	 change	of	 12	 (95%	CI	−6	 to	30;	P = 0.19)]. 
In sensitivity analysis, difference in median change was 6 (95% 
CI	−14	 to	26;	P = 0.55). In addition, mean (SD) change in eGFR 
from	 three	 to	 five	years	was	−15	 (16)	 in	CLKT	patients	 and	−3	
(15)	in	KT	patients	with	difference	in	mean	change	of	−12	(95%	
CI	 −24	 to	 0;	 P = 0.05) between groups. In sensitivity analysis, 
difference	 in	median	change	of	eGFR	was	−5	(95%	CI	−17	to	8;	
P = 0.44).
3.3.2 | Measured GFR in pediatric patients
Measured GFRs during the follow‐up period for pediatric CLKT and 
pediatric KT patients are shown in Figure 2C,D. Measured GFRs 
were also on average higher in CLKT patients compared to KT pa‐
tients. Differences in mean and median mGFRs (primary GFR analy‐
sis) are depicted in Table 3.
In secondary GFR analysis, mean (SD) change in mGFR from one 
to	three	years	after	CLKT	was	4	(11)	and	after	KT	−1	(6)	[difference	
in	mean	change	of	5	(95%	CI	−3	to	14;	P = 0.19)]. In sensitivity anal‐
ysis,	difference	in	median	change	of	mGFR	was	6	(95%	CI	−4	to	16;	
P = 0.26). In addition, mean (SD) change in mGFR from three to five 
years	in	CLKT	and	KT	patients	was	−8	(15)	and	−3	(10),	respectively.	
Therefore,	the	difference	in	mean	change	was	−5	(95%	CI	−16	to	6;	
P = 0.36) between groups. In sensitivity analysis, the difference in 
median	change	of	mGFR	was	−3	(95%	CI	−16	to	9;	P = 0.60).
3.3.3 | Estimated GFR in adult patients
Renal function deteriorated in both adult CLKT and KT patients during 
the follow‐up period albeit the drop in eGFR was more pronounced in 
CLKT than in KT patients at the beginning (Figure 3). Differences in 
mean and median eGFRs (primary GFR analysis) are shown in Table 4.
In secondary GFR analysis, mean (SD) change in eGFR from one to 
three	years	after	transplantation	was	−11	(13)	in	CLKT	patients	and	−4	
(18)	in	KT	patients	with	a	difference	in	mean	change	of	−7	(95%	CI	−14	
to 0; P = 0.05). In sensitivity analysis, the difference in median change 
was	−9	(95%	CI	−17	to	−1;	P = 0.03). In addition, mean (SD) change in 
eGFR	from	three	to	five	years	was	−2	(13)	in	CLKT	and	−3	(11)	in	KT	
patients	[difference	in	mean	change	of	1	(95%	CI	−5	to	8;	P = 0.68)]. In 
sensitivity	analysis,	the	difference	in	median	change	was	0	(95%	CI	−8	
to 8; P = 0.99).
Furthermore, results of linear mixed models are shown in Table 
S3. For instance, there was an approximately 2 to 3 mL/min/1.73 
m2 decrease in eGFR for every year of follow‐up across different 
models.
3.3.4 | Long‐term renal function of pediatric and 
adult CLKT patients
In five pediatric patients, mean (SD) eGFR and mGFR were 89 (17) 
and 70 (17) ten years after CLKT, respectively. In pairwise compari‐
son, mean (SD) eGFR increased from 82 (36) to 89 (17) (n = 5) from 
one to ten years after transplantation (95% CI for difference in mean 
−42	 to	 28;	P = 0.61). Furthermore, mGFR remained stable in four 
pediatric patients with a mean (SD) of 66 (13) at one year and with 
a mean (SD) of 66 (17) at ten years after transplantation (95% CI for 
difference	in	mean	−30	to	30;	P = 0.97).
In nine adult patients, mean (SD) eGFR was 50 (16) ten years 
after CLKT. In pairwise comparison, mean (SD) eGFR decreased from 
66 (24) to 51 (18) (n = 7) from one to ten years after transplantation 
(95% CI for difference in mean 5 to 25; P = 0.01).
In sensitivity analyses, bootstrapped CIs were altogether similar 
in pairwise comparisons (not shown).
3.3.5 | Comparison of estimated GFR and measured 
GFR in CLKT patients
Mean mGFR was 60 (12) in 10 pediatric patients at last follow‐up 
with a mean (SD) follow‐up time of 10.2 (3.9) years after CLKT. Mean 
TA B L E  2   Characteristics of 96 KT control patients
 
Adult patients 
(N = 69)
Pediatric 
patients (N = 27)
Gender, n (%)
Male 33 (47.8) 12 (44.4)
Female 36 (52.2) 15 (55.6)
Mean (SD) age at KT, 
years
44.8 (15.8)a  4.9 (4.3)b 
Mean (SD) CIT, hours 21.8 (4.3)c  17.3 (5.3)d 
Mean (SD) donor age, 
years
42.0 (13.2)e  37.8 (14.6)f 
Primary indication for KT, n (%)
Diabetic nephropathy 15 (21.7) ‐
CNF ‐ 15 (55.6)
PKD 11 (15.9) 1 (3.7)
CKD, unspecified 10 (14.5) 3 (11.1)
Chronic 
glomerulonephritis
8 (11.6) ‐
IgA	nephropathy 7 (10.1) ‐
Chronic tubulointer‐
stitial nephritis
5 (7.2) ‐
Miscellaneous 13 (18.8) 8 (29.6)
KT era, n (%)
1992‐1996 5 (7.2) ‐
1997‐2001 14 (20.3) 6 (22.2)
2002‐2006 33 (47.8) 13 (48.1)
2007‐2012 17 (24.6) 8 (29.6)
aMedian (IQR) 45.1 (23.7 to 59.1). 
bMedian (IQR) 2.4 (1.6 to 10.0). 
cMedian (IQR) 21.2 (18.8 to 24.7). 
dMedian (IQR) 18.4 (16.7 to 21.0). 
eMedian (IQR) 45.0 (33.0 to 51.0). 
fMedian (IQR) 39.0 (25.3 to 50.2). 
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(SD) mGFR was 54 (22) in 12 adult patients taken cross‐sectionally 
during the follow‐up with a mean (SD) follow‐up time of 6.7 (3.7) 
years after CLKT.
Mean	difference	(95%	LOA)	of	estimated	minus	measured	GFR	
was	14	(−10	to	37)	in	these	10	pediatric	patients	and	11	(−12	to	34)	
in these 12 adult patients (Figure 4). In both pediatric and adult 
patients, seven eGFRs were within mGFR interval of ± 30% re‐
flecting an accuracy (ie, P30) (95% CI) of 70% (40% to 89%) and 
58% (32% to 81%) for bedside Schwartz and CKD‐EPI equation, 
respectively.
3.4 | Other results
Correlation coefficients between eGFR and calcineurin inhibitor 
trough levels are shown in Table S4.
There was no drastic abnormality of selected laboratory tests in 
pediatric CLKT patients (Table S5). In adult CLKT patients, median 
total bilirubin was within normal range while mean total bilirubin was 
elevated due to an outlying value.
4  | DISCUSSION
Our study demonstrates that renal function remained stable in 
pediatric CLKT patients with long‐term follow‐up, contrary to 
what was observed in adult CLKT patients. When renal function 
of CLKT patients was contrasted to renal function of KT patients, 
a somewhat similar pattern occurred in eGFR in the transplanta‐
tion groups during the follow‐up period of the pediatric and adult 
patients.
F I G U R E  1   Patient survival for 11 
pediatric and 23 adult combined liver‐
kidney transplant (CLKT) patients. One‐, 
five‐, and ten‐year patient survivals (95% 
CI) for pediatric patients were 91% (51% 
to 99%), 91% (51% to 99%), and 81% 
(42% to 95%), and one‐, five‐, and ten‐
year patient survivals (95% CI) for adult 
patients were 100%, 96% (73% to 99%), 
and 70% (44% to 85%)
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F I G U R E  2  Estimated	(A	and	B)	and	
measured (C and D) GFR for pediatric 
combined liver‐kidney transplant (CLKT) 
patients	(A	and	C)	and	for	pediatric	kidney	
transplant (KT) patients (B and D) after 
transplantation. Mean and median GFR is 
shown with black solid and dashed lines, 
respectively. Mean (median) estimated 
GFR for CLKT and KT patients at one, 
three, and five years were 82 (82), 102 
(96), 86 (79) and 63 (56), 71 (65), 68 (58), 
respectively. Mean (median) measured 
GFR for CLKT and KT patients at one, 
three, and five years were 63 (63), 69 
(70), 61 (63) and 55 (47), 54 (49), 50 
(50), respectively. Note the different 
scale	between	estimated	(A	and	B)	and	
measured GFR (C and D)
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Our long‐term results of eGFR are better or comparable to other 
pediatric CLKT single‐center studies.15,27‐29 In two of these studies, 
eGFR was around 70 mL/min/1.73 m2 at last evaluation with varying 
follow‐up times.27,28 However, the follow‐up times were, on aver‐
age, shorter than in our cohort. In two other studies, there was a 
13 to 18 mL/min/1.73 m2 drop in eGFR from one to ten years after 
 Year 1 Year 3 Year 5
Estimated GFR
Mean (SD)
CLKT patientsa  82 (30) 102 (30) 86 (26)
KT patientsb  63 (28) 71 (26) 68 (32)
Difference (95% CI) c  19	(−4	to	42) 31 (8 to 54) 19	(−2	to	40)
Median (IQR)
CLKT patients 82 (57 to 100) 96 (83 to 131) 79 (71 to 99)
KT patients 56 (47 to 70) 65 (54 to 90) 58 (50 to 80)
Difference (95% CI) d  26	(−6	to	58) 31 (2 to 60) 21	(−3	to	45)
Measured GFR
Mean (SD)
CLKT patientse  63 (17) 69 (17) 61 (19)
KT patientsf  55 (19) 54 (20) 50 (20)
Difference (95% CI) c  8	(−7	to	23) 16 (1 to 30) 11	(−4	to	26)
Median (IQR)
CLKT patients 63 (51 to 75) 70 (55 to 82) 63 (47 to 73)
KT patients 47 (40 to 69) 49 (42 to 75) 50 (37 to 60)
Difference (95% CI)d  16	(−2	to	34) 21 (0 to 41) 13	(−8	to	35)
GFRs were estimated with bedside Schwartz equation and measured with 51Cr‐EDTA	clearance.	
GFRs and respective differences are rounded to the nearest whole number and shown with unit of 
mL/min/1.73 m2. IQRs are 25th to 75th percentiles and might slightly differ from Figure 2.
an=10 at all time‐points. 
bn=27 at all time‐points. 
cBased	on	Welch's	t test; P‐values 0.09, 0.01, 0.08 for estimated and 0.27, 0.03, 0.14 for measured 
GFR at one, three, and five years, respectively. 
dBased on Bonett‐Price method; P‐values 0.11, 0.04, 0.09 for estimated and 0.09, 0.05, 0.23 for 
measured GFR at 1, 3, and 5 y, respectively. 
en=9, n = 10, n = 10 at 1, 3, and 5 y, respectively. 
fn=21, n = 26, n = 25 at 1, 3, and 5 y, respectively. 
TA B L E  3   Comparison of GFR for 
pediatric combined liver‐kidney transplant 
and kidney transplant patients
F I G U R E  3  Estimated	GFR	for	adult	combined	liver‐kidney	transplant	(CLKT)	patients	(A)	and	for	adult	kidney	transplant	(KT)	patients	(B)	
after transplantation. Mean and median GFR is shown with black solid and dashed lines, respectively. Mean (median) GFR for CLKT and KT 
patients at one, three, and five years were 75 (74), 64 (63), 62 (56) and 67 (62), 64 (59), 61 (57), respectively
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CLKT.15,29 In contrast, we observed some improvement in eGFR 
from	 one	 to	 ten	 years.	 Additionally,	 depending	 on	 analytical	 ap‐
proach, mGFR increased or remained stable in our study between 
one and ten years. Naturally, there might be number of reasons for 
these different eGFR patterns observed between our study and 
these two studies. Unfortunately, mGFRs were not available in ei‐
ther of the two studies.
We observed a decline in renal function of adult CLKT patients 
during	 the	 follow‐up	 period.	Although	 some	 studies	 have	 demon‐
strated stable renal function after CLKT,16 similar findings to ours 
have also been reported by others.13,14 Singal et al 13 demonstrated 
that eGFR declined in some but not in other patient groups indicating 
that primary diagnosis may have a role in renal function after CLKT. 
Interestingly, mean eGFR in our two primary hyperoxaluria patients 
with their native kidneys was 51 at one, 96 at five, and 87 at 10 years 
after CLKT. Ranawaka et al 15 reported mean eGFR around 50 in 
their primary hyperoxaluria patients from one to ten years after 
CLKT.
A	similar	pattern	 in	both	adult	 and	pediatric	patients	occurred	
when renal function of CLKT patients was assimilated to KT pa‐
tients. The pediatric CLKT and KT patients showed improvement in 
eGFR from one to three years after transplantation followed by a 
downturn from three to five years after transplantation. This pattern 
was also evident in pediatric CLKT patients but not in pediatric KT 
 Year 1 Year 3 Year 5
Estimated GFR
Mean (SD)
CLKT patientsa  75 (26) 64 (21) 62 (21)
KT patientsb  67 (24) 64 (25) 61 (24)
Difference (95% CI)c  8	(−5	to	20) 0	(−11	to	11) 1	(−10	to	12)
Median (IQR)
CLKT patients 74 (51 to 101) 63 (48 to 83) 56 (48 to 73)
KT patients 62 (50 to 83) 59 (45 to 80) 57 (42 to 75)
Difference (95% CI)d  12	(−9	to	33) 4	(−12	to	20) −1	(−15	to	13)
GFRs were estimated with CKD‐EPI equation and are shown with mL/min/1.73 m2. GFRs and re‐
spective differences are rounded to the nearest whole number. IQRs are 25th to 75th percentiles 
and might slightly differ from Figure 3.
an=23, n = 23, and n = 21 at 1, 3, and 5 y, respectively. Mean (median) GFR 77 (78), 66 (66), and 63 
(58) when GFRs outside ± three months were excluded. 
bn=69, n = 64, and n = 63 at 1, 3, and 5 y, respectively. Mean (median) GFR 70 (62), 67 (66), and 61 
(56) when GFRs outside ±  three months were excluded. 
cBased	on	Welch's	t test; P‐values 0.21, >0.99, and 0.86 at 1, 3, and 5 y, respectively. 
dBased on Bonett‐Price method; P‐values 0.25, 0.64, and 0.89 at 1, 3, and 5 y, respectively. 
TA B L E  4   Comparison of estimated 
GFR for adult combined liver‐kidney 
transplant and kidney transplant patients
F I G U R E  4  Bland‐Altman	plots	for	
estimated and measured (GFR; mL/
min/1.73 m2)	in	pediatric	(A,	n	=	10)	and	
adult (B, n = 12) combined liver‐kidney 
transplant (CLKT) patients. Bedside 
Schwartz equation was used in pediatric 
and CKD‐EPI equation in adult patients 
for GFR estimation. Measured GFRs 
were taken at last follow‐up for pediatric 
patients and in a cross‐sectional manner 
during the follow‐up for adult patients. 
Mean (SD) difference (black solid line) of 
estimated minus measured GFR 14 (12) in 
pediatric and 11 (12) in adult patients. Line 
above zero indicates overestimation and 
below zero underestimation of measured 
GFR with the use of GFR estimation 
equation.	Ninety‐five	percent	LOA	are	
shown with dashed lines
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patients when focused on mGFR. Contrary, adult CLKT and KT pa‐
tients showed decline in eGFR during the follow‐up.
Comparison of our study and two other studies15,16 that have 
contrasted renal function of CLKT patients to KT patients beyond 
one year after transplantation is shown in Table 5. Ranawaka et al15 
showed that mean eGFR was higher in pediatric CLKT compared to 
pediatric KT patients which is in line with ours although GFR remained 
stable in our pediatric patients. Taner et al16 demonstrated that eGFR 
deteriorated in KT patients and the deterioration depended on donor‐
specific antibody status.16 Our adult CLKT and KT patients had higher 
mean eGFRs than in study by Taner et al16 although their patient pop‐
ulation consisted of mostly adult but some pediatric patients as well.
Donor age in our pediatric CLKT patients was lower compared 
to pediatric KT patients, which might explain the on average higher 
GFRs in pediatric CLKT patients. In the aforementioned study,16 
donor age was not materially associated with graft loss or GFR de‐
cline over 50% (ie, functional decline). In a small sample of pediatric 
KT patients, inclusion of donor age did not improve model perfor‐
mance for GFR prediction.30
GFRs based on estimation equations were on average higher 
than GFRs based on measurement with 51Cr‐EDTA	plasma	clearance	
in our small sample of CLKT patients. In adults, CKD‐EPI equation 
has shown to overestimate or underestimate mGFR in studies with 
mean follow‐up ranging from 5 to 7 years after KT or LT.31,32 Mean 
mGFR was 54 in our adult CLKT patients which is comparable to 
other studies.31,32 There are various GFR estimation equations, and 
we decided to use CKD‐EPI equation. However, both CKD‐EPI and 
MDRD equations have been pointed out as useful in solid organ 
transplantation population.33 In pediatric KT patients, bedside 
Schwartz equation has shown to overestimate mGFR based on a 
renal inulin clearance albeit providing acceptable 30% accuracy even 
in lower mGFR levels.34 However, since mGFRs were taken routinely 
in our pediatric patients, the choice to use one estimation equation 
over another is less important one.
Our study has some limitations. First, the number of CLKT pa‐
tients was small. Second, control patients were not selected ran‐
domly, which might have introduced selection bias. Future studies 
should	address	our	study's	aforementioned	limitations.	Our	study's	
 
Study
Current study Ranawaka et al Taner et al
Patient population Adult	and	pediatric Pediatric Adult	and	
pediatric
Number of patients
CLKT 33 40 68
KT 96 40 136
Matching ratio 1:2.9 1:1 1:2
Matched for age and gender Yes Age	yes	(gender	no) Yes
Mean time from CLKT, years 8.8 to 10.2a  6.4 6.2 to 7.1b 
Median donor age, y
CLKT 11 to 39 ‐ 37 to 41
KT 39 to 45 ‐ 39 to 40
Method to determine GFR Estimation and 
measurement
Estimation 
(Schwartz)
Estimation 
(MDRD)
Time‐points for GFR 1, 3, and 5 years 1, 5, and 10 years 4 months and 
5 years
Mean GFR at one and five yearsc 
Pediatric CLKT 82 to 86 68 to 59  
Pediatric KT 63 to 68 63 to 52  
Adult	CLKT 75 to 62 ‐ 60 to 60d 
Adult	KT 67 to 61 ‐ 52 to 48e 
Mean or median is shown for continuous variables to simplify comparison between current study 
and two other studies (references 15 and 16).
aFollow‐up time for 23 adult and 10 pediatric CLKT patients, respectively. 
bFollow‐up	time	for	14	DSA‐positive	and	54	DSA‐negative	CLKT	patients,	respectively.	
cEstimated GFRs (mL/min/1.73 m2) at one and five years to simplify comparison between studies. 
First GFR at four months in Taner et al. 
dValues	are	rounded	and	are	for	DSA‐negative	CLKT	patients.	For	DSA‐positive	CLKT	patients,	re‐
spective GFRs 56 to 57. 
eValues	are	rounded	and	are	for	DSA‐negative	KT	patients.	For	DSA‐positive	KT	patients,	respective	
GFRs 60 to 44. 
TA B L E  5   Characteristics of three 
studies that have compared renal function 
of CLKT patients to KT patients
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strength is that measured GFRs were routinely taken in our pediatric 
patients and once during the follow‐up from adult CLKT patients, 
which broadens our long‐term renal function results. In addition, all 
patients were treated and followed at one center by two closely co‐
operating pediatric and adult units.
From a statistical perspective, our primary and secondary GFR 
analyses were simple. We assumed that CLKT and KT groups are 
independent. However, additional analyses for adult patients with 
linear mixed models were also made to account non‐independency 
of observations. We only adjusted matched variables in addition to 
group and time according to our modeling objective. Undoubtedly, 
there can be various factors, such as donor characteristics or im‐
munological aspects (for example, donor‐specific antibodies) among 
other things that might have effect on observed renal function. We 
opted out of linear mixed models in pediatric patients since the 
number of patients was small. We did not dichotomize our results 
to statistically significant or non‐significant since there are problems 
with this approach, as has been emphasized elsewhere35 and also in 
transplantation literature.36
In conclusion, longitudinal changes in GFRs were somewhat sim‐
ilar in CLKT and KT patients in both age‐groups but pediatric CLKT 
patients had on average higher GFRs than pediatric KT patients. 
Renal function remains stable with long‐term follow‐up in pediatric 
CLKT patients but declines in adult CLKT patients.
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